Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
Shares of ThromboGenics (TBGNF) are higher after Novartis (NOV) and Shire (SHPG) were said to be among drugmakers considering offers for the Belgian eye-medicine company.
BioLineRx announced that Prof. Arnon Nagler was given the final regulatory approval to evaluate BL-8040 in a phase I/II study for the treatment of CML.
We believe The Cooper Companies is poised for growth given its significant market share in high growth specialty lenses.
Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.
TheStreet highlights 3 stocks pushing the drugs industry lower today.